𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumour thickness and the site and time of first recurrence in cutaneous malignant melanoma (stage I)

✍ Scribed by O. W. Milton; H. M. Shaw; G. A. Farago; W. H. McCarthy


Publisher
John Wiley and Sons
Year
1980
Tongue
English
Weight
365 KB
Volume
67
Category
Article
ISSN
0007-1323

No coin nor oath required. For personal study only.

✦ Synopsis


Summary

A study was made of 326 patients first treated for clinical stage I cutaneous malignant melanoma by a wide excision (with or without split-skin graft) but no nodal dissection and who subsequently developed recurrence of their disease. Thick lesions recurred far more frequently than very thin lesions, although evidence of partial regression in very thin lesions conferred upon the latter a liability to metastasize. Thicker lesions first recurred predominantly in the vicinity of the scar of primary lesion excision whilst very thin lesions first recurred either at regional lymph nodes or at remote sites. The disease-free interval fell with increasing tumour thickness. As a result of this, local first recurrences developed more rapidly than remote first recurrences. The cumulative 10-year survival rate for patients with local first recurrences was, however, significantly higher than for patients with remote first recurrences, as the survival period after local first recurrence was considerably longer than after remote first recurrence.

We conclude that tumour thickness is an easily measured, objective predictor of the site and time of first recurrence from melanoma. Thus, by facilitating early detection of first metastastases, it may be possible to prolong survival time.


πŸ“œ SIMILAR VOLUMES


Treatment outcome for 424 primary cases
✍ William J. Kane; Patricia Yugueros; Ricky P. Clay; John E. Woods πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 English βš– 103 KB πŸ‘ 2 views

Background. Cutaneous malignant melanoma (CMM) is increasing in frequency. Surgery remains the primary and only curative treatment method. Our aim was to define prognostic factors and outcome predictors for patients with clinical stage I CMM of the head and neck. Methods. Surgical treatment and out

Loss of expression of the p16INK4/CDKN2
✍ Lauri Talve; Ilari Sauroja; YrjΓΆ Collan; Kari Punnonen; Tauno Ekfors πŸ“‚ Article πŸ“… 1997 πŸ› John Wiley and Sons 🌐 French βš– 155 KB πŸ‘ 2 views

The G 1 /S checkpoint of the cell cycle is regulated by p16, p53 and RB tumor suppressor genes. Loss of expression of the p16 INK4 tumor suppressor protein, the product of the CDKN2 gene, has been associated with a wide variety of human malignancies. Mutations, loss of heterozygosity and deletions o